

In re Rasmussen et al.
Application No. 09/550,857
December 10, 2004

Page 3 of 3
5866.200-US (previously NN 26)
Art Unit 1623

REMARKS

The Office is requested to kindly use attorney docket number 5866.200-US for all future correspondence regarding this application.

The previously pending claims contained within claims 1-63 and claim 68 are hereby cancelled so as to limit the issues in this case for appeal (a Notice of Appeal is filed contemporaneously). As previously indicated, the Office has failed to properly set forth a case of *prima facie* anticipation or obviousness with respect to these claims. Accordingly, reversal of the previously made rejections, particular with respect to these claims, is warranted. Applicants reserve the right to pursue the hereby cancelled claims in this or a related application, and the cancellation of these claims here is in no way a concession of correctness of the rejection of these claims.

In view of the above, it is respectfully submitted that all claims are in condition for allowance. Early action to that end is respectfully requested. The Commissioner is hereby authorized to charge any fees in connection with this application and to credit any overpayments to Deposit Account No. 14-1447. The Examiner is invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,



Date: December 10, 2004

Len S. Smith, Reg. No. 43,139
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE